Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 5:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 1,096 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control Vehicle Clear all
Completed Phase 3 Interventional Results available

A Study to Evaluate Safety and Equivalence of Generic Azelaic Acid Foam and Finacea® Foam in Participants With Rosacea

NCT03287791
View directory record Official record
Conditions
Rosacea
Interventions
Generic Azelaic Acid Foam, Finacea® (Azelaic Acid) Foam, Vehicle Foam, Cleanser, Sunscreen, Towel, Moisturizing Lotion
Drug · Other
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years and older
Enrollment
924 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
26
States / cities
Encino, California • La Mesa, California • Brandon, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2019 · Synced Oct 18, 2026, 5:01 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19

NCT04402060
View directory record Official record
Conditions
COVID, Covid-19, Coronavirus, Coronavirus Infection, Severe Acute Respiratory Syndrome, Severe Acute Respiratory Syndrome Coronavirus 2, Sars-CoV2, Ards, Acute Respiratory Distress Syndrome
Interventions
APL-9, Vehicle Control
Drug · Other
Lead sponsor
Apellis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
16
States / cities
Fresno, California • San Francisco, California • Jacksonville Beach, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2022 · Synced Oct 18, 2026, 5:01 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Dose Ranging Study to Assess the Efficacy and Safety of Voclosporin Ophthalmic Solution in Subjects With Dry Eye Syndrome

NCT04147650
View directory record Official record
Conditions
Dry Eye Syndrome, Keratoconjunctivitis Sicca
Interventions
0.05% Voclosporin Ophthalmic Solution (VOS), 0.10% VOS, 0.20% VOS, Vehicle Ophthalmic Solution
Drug
Lead sponsor
Aurinia Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
508 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
9
States / cities
Newport Beach, California • Colorado Springs, Colorado • Louisville, Kentucky + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2021 · Synced Oct 18, 2026, 5:01 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Efficacy of IDP-118 Lotion in the Treatment of Plaque Psoriasis

NCT02785159
View directory record Official record
Conditions
Psoriasis
Interventions
IDP-118 Lotion, Tazorac Cream, IDP-118 Vehicle Lotion, IDP-118 Vehicle Cream
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
14
States / cities
Encino, California • Orange Park, Florida • Pinellas Park, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2020 · Synced Oct 18, 2026, 5:01 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle Controlled, Parallel-Group, Clinical Study in the Treatment of Acne Vulgaris

NCT03170388
View directory record Official record
Conditions
Acne Vulgaris
Interventions
IDP-126 Gel, IDP-126 Component A, IDP-126 Component B, IDP-126 Component C, IDP-126 Vehicle Gel
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
9 Years to 99 Years
Enrollment
741 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
29
States / cities
Hot Springs, Arkansas • Fremont, California • Sacramento, California + 24 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2021 · Synced Oct 18, 2026, 5:01 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

New Functional Ingredient for Oral Care

NCT07771907
View directory record Official record
Conditions
Oral Health Related Quality of Life (OHRQoL)
Interventions
Botanical A, Botanical B, Vehicle (Placebo solution)
Dietary Supplement
Lead sponsor
Access Business Group
Industry
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Grand Rapids, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 18, 2026, 5:01 AM EDT
Completed Phase 2 Interventional

Study to Evaluate the Safety and Efficacy of Topical Minocycline Gel in Patients With Papulopustular Rosacea

NCT03263273
View directory record Official record
Conditions
Rosacea, Papulopustular Rosacea
Interventions
1% Topical Minocycline Gel, 3% Topical Minocycline Gel, Topical Vehicle Gel
Drug · Other
Lead sponsor
Hovione Scientia Limited
Industry
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
23
States / cities
Bryant, Arkansas • Rogers, Arkansas • Fremont, California + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2019 · Synced Oct 18, 2026, 5:01 AM EDT
Withdrawn Phase 2 Interventional

Efficacy Study of Ketorolac and HPMC to Treat Dry Eye

NCT03693183
View directory record Official record
Conditions
Dry Eye
Interventions
Ketorolac/HPMC, HPMC, Vehicle
Drug
Lead sponsor
ORA, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Oct 18, 2026, 5:01 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety of XG-102 in Reduction of Post-cataract Surgery Intraocular Inflammation

NCT02235272
View directory record Official record
Conditions
Inflammation, Pain, Cataract
Interventions
XG-102, Placebo
Drug
Lead sponsor
Xigen SA
Industry
Eligibility
18 Years and older
Enrollment
339 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Garden Grove, California
Source: ClinicalTrials.gov public record
Updated Jan 24, 2017 · Synced Oct 18, 2026, 5:01 AM EDT
Not listed Phase 3 Interventional Results available

A Study Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy in Untreated Metastatic Breast Cancer (RIBBON 1)

NCT00262067
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Bevacizumab, Placebo, Chemotherapy
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
5
States / cities
Fullerton, California • Santa Barbara, California • Iowa City, Iowa + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2013 · Synced Oct 18, 2026, 5:01 AM EDT
Completed Phase 2 Interventional Results available

Study to Investigate the Safety and Efficacy of K-321 in Patients With Fuchs Endothelial Corneal Dystrophy (FECD) Following Descemetorhexis

NCT04250207
View directory record Official record
Conditions
Fuchs' Endothelial Corneal Dystrophy
Interventions
K-321 Solution, Placebo Solution
Drug
Lead sponsor
Kowa Research Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
19
States / cities
Los Angeles, California • Palo Alto, California • Sacramento, California + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2024 · Synced Oct 18, 2026, 5:01 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Study of the Safety and Efficacy of Ruxolitinib Cream for Non-Sclerotic Chronic Cutaneous Graft-Versus-Host Disease

NCT03954236
View directory record Official record
Conditions
Non-sclerotic Cutaneous Chronic Graft-versus-host Disease
Interventions
topical ruxolitinib 1.5% cream, Topical vehicle/moisturizer cream
Drug · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
12 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 18, 2026, 5:01 AM EDT
Completed Phase 4 Interventional Results available

Combination Therapy for Atopic Dermatitis

NCT00119158
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Combination of pimecrolimus and fluticasone, pimecrolimus
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
2 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
3
States / cities
Denver, Colorado • Chicago, Illinois • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 27, 2010 · Synced Oct 18, 2026, 5:01 AM EDT
Completed Phase 4 Interventional Results available

A Five Day Clinical Study to Examine the Effects of a Benzoyl Peroxide Treatment on Facial Acne Lesions

NCT02052752
View directory record Official record
Conditions
Skin Diseases
Interventions
3% Benzoyl Peroxide, 3% Benzoyl Peroxide Placebo, Neutrogena Rapid Clear®
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years to 45 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated May 18, 2015 · Synced Oct 18, 2026, 5:01 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN)

NCT05755438
View directory record Official record
Conditions
Prurigo
Interventions
Ruxolitinib Cream, Vehicle Cream
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 99 Years
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
18
States / cities
Phoenix, Arizona • Fort Smith, Arkansas • Fountain Valley, California + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 18, 2026, 5:01 AM EDT
Completed Phase 3 Interventional Results available

A Study for Evaluation of the Efficacy and Safety of SI-614 Ophthalmic Solution in Patient With Dry Eye

NCT05411367
View directory record Official record
Conditions
Dry Eye Disease
Interventions
SI-614, Placebo
Drug
Lead sponsor
Seikagaku Corporation
Industry
Eligibility
18 Years and older
Enrollment
232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
6
States / cities
Newport Beach, California • Louisville, Kentucky • Andover, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2026 · Synced Oct 18, 2026, 5:01 AM EDT
Completed Phase 2 Interventional Results available

A Dose Ranging Study of the Effect of Ruxolitinib Phosphate Cream When Applied to Participants With Plaque Psoriasis

NCT00778700
View directory record Official record
Conditions
Psoriasis
Interventions
Placebo Cream, Ruxolitinib Phosphate
Other · Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
28
States / cities
Hot Springs, Arkansas • Los Angeles, California • San Diego, California + 25 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2022 · Synced Oct 18, 2026, 5:01 AM EDT
Completed Phase 3 Interventional Results available

Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome : ARISE-2

NCT02974907
View directory record Official record
Conditions
Dry Eye Syndrome
Interventions
RGN-259, Placebo
Drug
Lead sponsor
ReGenTree, LLC
Industry
Eligibility
18 Years and older
Enrollment
601 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 5, 2022 · Synced Oct 18, 2026, 5:01 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy of VDMN-21 Patch in Subjects With Common Warts

NCT05799157
View directory record Official record
Conditions
Verruca Vulgaris, Warts, Common Wart
Interventions
VDMN-21 Patch Low Dose, VDMN-21 Patch High Dose, Vehicle Patch
Drug
Lead sponsor
Veradermics, Inc.
Industry
Eligibility
9 Years to 65 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
16
States / cities
Fort Smith, Arkansas • San Diego, California • Plainfield, Indiana + 13 more
Source: ClinicalTrials.gov public record
Updated May 8, 2025 · Synced Oct 18, 2026, 5:01 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Efficacy and Safety of IDP-124 Lotion for the Treatment of Moderate to Severe Atopic Dermatitis in Pediatric and Adult Subjects (301)

NCT03002571
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
IDP-124 Lotion, IDP-124 Vehicle Lotion
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
2 Years and older
Enrollment
338 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Fort Lauderdale, Florida
Source: ClinicalTrials.gov public record
Updated May 8, 2023 · Synced Oct 18, 2026, 5:01 AM EDT
Completed Phase 3 Interventional

A Clinical Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease

NCT06424444
View directory record Official record
Conditions
Dry Eye Disease
Interventions
Reproxalap ophthalmic solution (0.25%), Vehicle ophthalmic solution
Drug
Lead sponsor
Aldeyra Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
421 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Shelby, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Oct 18, 2026, 5:01 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Aggressive Driving and Road Rage: A Driving Simulation Experiment.

NCT03430973
View directory record Official record
Conditions
Aggression
Interventions
Videos, Bumper stickers, Alcohol-related cues, Music, Roadside vegetation, Video game
Behavioral
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2025
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 19, 2025 · Synced Oct 18, 2026, 5:01 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of AN2690 Topical Solution to Treat Onychomycosis of the Toenail

NCT01302119
View directory record Official record
Conditions
Onychomycosis of Toenails
Interventions
AN2690 Topical Solution, 5%, Solution Vehicle
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
604 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
26
States / cities
Phoenix, Arizona • Novato, California • Oceanside, California + 22 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2019 · Synced Oct 18, 2026, 5:01 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Generic Tazarotene Cream, 0.05% for the Treatment of Plaque Psoriasis

NCT02160665
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Tazarotene Cream, 0.05%, Vehicle, Reference: Tazorac Cream, 0.05%
Drug
Lead sponsor
G & W Laboratories Inc.
Industry
Eligibility
18 Years and older
Enrollment
866 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Arlington Heights, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 3, 2016 · Synced Oct 18, 2026, 5:01 AM EDT